Physician profile
Mayte L Sandrin
NPI 1437129525
$10,152.11
in general payments reported to CMS, 2019-2025
48 companies · $2,292 in 2025
The $2,292 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,090 · 2020: $508 · 2021: $893 · 2022: $947 · 2023: $1,704 · 2024: $1,719 · 2025: $2,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,672 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,672.47 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,592.44 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,299.58 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $1,035.55 | 2019-2025 | Evenity, Tepezza, Prolia |
| Insulet Corporation | $854.92 | 2019-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $689.63 | 2019-2025 | |
| Dexcom, INC. | $575.37 | 2019-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $470.51 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novo Nordisk INC | $385.26 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.55 | 2019-2025 | Jardiance |
| Radius Health, INC. | $250.81 | 2019-2025 | Tymlos |
| Mannkind Corporation | $222.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.91 | 2019-2025 | Lokelma |
| Xeris Pharmaceuticals, INC. | $196.62 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $179.09 | 2025 | Yorvipath |
| Eisai INC. | $133.56 | 2019-2020 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $115.49 | 2023-2024 | |
| Becton, Dickinson and Company | $114.05 | 2019-2020 | |
| Ibsa Pharma INC. | $102.70 | 2019-2021 | |
| Abbvie INC. | $101.11 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $96.09 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $89.11 | 2019 | |
| Medtronic, INC. | $88.08 | 2021-2025 | Intellis Adaptivestim, Minimed 780g |
| Recordati_rare_diseases_inc. | $84.11 | 2021-2025 | Signifor Lar, Isturisa |
| Sequel Med Tech, LLC | $82.44 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $80.44 | 2020-2022 | |
| Chiasma, INC. | $61.99 | 2021 | |
| Halozyme INC | $61.04 | 2023 | |
| Amarin Pharma, INC. | $57.53 | 2019-2021 | |
| Cequr Corporation | $50.92 | 2023-2025 | Cequr Simplicity |
| Medtronic Minimed, INC. | $46.66 | 2019 | |
| Neurocrine Biosciences, INC. | $44.18 | 2024-2025 | |
| Pfizer INC. | $34.80 | 2019-2024 | |
| Averitas Pharma INC. | $34.52 | 2024 | Qutenza |
| Valeritas, INC. | $34.11 | 2019 | |
| Nevro Corp. | $29.91 | 2023 | Senza |
| Horizon Therapeutics Plc | $29.25 | 2021 | |
| Antares Pharma, INC. | $29.03 | 2019-2025 | Xyosted |
| Chiesi USA, INC. | $27.41 | 2025 | Mycapssa |
| Lifescan, INC. | $27.27 | 2019-2021 | |
| Beta Bionics, INC. | $25.76 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Madrigal Pharmaceuticals | $18.36 | 2025 | Rezdiffra |
| Shire North American Group INC | $18.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.24 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.46 | 2019 | |
| Esperion Therapeutics, INC. | $15.03 | 2022 | |
| Globus Medical, INC. | $13.97 | 2025 | Senza |
| Intuity Medical INC | $13.42 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Ipsen Biopharmaceuticals, INC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayte Sandrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.